You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,045,293


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,045,293
Title:Alteration of sequence of a target molecule
Abstract: Method for splicing a target nucleic acid molecule with a separate nucleic acid molecule. Such splicing generally causes production of a chimeric protein with advantageous features over that protein naturally produced from the target nucleic acid prior to splicing. The method includes contacting the target nucleic acid molecule with a catalytic nucleic acid molecule including the separate nucleic acid molecule. Such contacting is performed under conditions in which at least a portion of the separate nucleic acid molecule is spliced with at least a portion of the target nucleic acid molecule to form a chimeric nucleic acid molecule. In this method, the catalytic nucleic molecule is chosen so that it is not naturally associated with the separate nucleic acid molecule.
Inventor(s): Sullenger; Bruce (Westminster, CO), Cech; Thomas R. (Boulder, CO)
Assignee: The Regents of the University of Colorado (Boulder, CO)
Application Number:10/799,535
Patent Claims:1. Method for splicing a target RNA molecule comprising a mutant p53 nucleotide sequence within a cell in culture with a separate RNA molecule comprising a wild type p53 nucleotide sequence, wherein a protein product of the target RNA molecule is deleterious to the cell in which it is located, and wherein the separate RNA molecule is adapted to form a target RNA molecule with the wild type p53 nucleotide sequence in place of mutant p53 nucleotide sequence when spliced with at least a part of the target RNA molecule, the method comprising: contacting the target RNA molecule with a catalytic RNA molecule comprising the separate RNA molecule, under conditions in which at least a portion of the separate RNA molecule is spliced with at least a portion of the target RNA molecule to form the target RNA molecule with the wild type p53 nucleotide sequence in place of mutant p53 nucleotide sequence when spliced with at least a part of the target RNA molecule.

2. The method of claim 1, wherein the catalytic RNA molecule is active to cleave the target RNA molecule comprising a mutant p53 nucleotide sequence and to splice the separate RNA molecule with the target RNA molecule comprising a mutant p53 nucleotide sequence.

3. The method of claim 1, wherein the contacting is in vitro.

4. The method of claim 3, wherein the contacting comprises providing a vector encoding the catalytic RNA molecule, wherein the catalytic RNA molecule includes the separate RNA molecule comprising a wild-type p53 nucleotide sequence.

5. The method of claim 1, wherein the catalytic RNA molecule is derived from a group I or group II intron molecule.

Details for Patent 7,045,293

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2013-11-12
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2013-11-12
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2013-11-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.